含Ⅲ型纖連蛋白域蛋白5(FNDC5)活性蛋白
Active Fibronectin Type III Domain Containing Protein 5 (FNDC5)
FRCP2; Irisin; Fibronectin type III repeat-containing protein 2
- 編號(hào)APN576Hu01
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 80%
- 等電點(diǎn)6.2
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 1267 ¥ 3168 ¥ 6336 ¥ 19008 ¥ 47520
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Figure. SDS-PAGE
-
WB圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
活性實(shí)驗(yàn)
Fibronectin type III domain-containing protein 5, the precursor of?irisin, is a?protein?that is encoded by the FNDC5?gene. FNDC5 is a 12?kDa glycosylated polypeptide hormone that regulate glycolipid metabolism, cardiovascular homeostasis metabolism, stem cell differentiation, and neuronal development. Myostatin (MSTN) has been identified as an interactor of FNDC5, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human FNDC5 and recombinant human MSTN. Briefly, FNDC5 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to MSTN-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-FNDC5 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant human FNDC5 and recombinant human MSTN was shown in Figure 1, the EC50?for this effect is 0.03 ug/mL.
用法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月，-80°C不超過(guò)12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPN576Hu05 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPN576Hu06 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPN576Hu07 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPN576Hu02 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| EPN576Hu61 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPN576Hu03 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPN576Hu01 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APN576Hu01 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)活性蛋白 | Cell?culture;?Activity?Assays. |
| APN576Hu61 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPN576Hu04 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAN576Hu02 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)多克隆抗體 | WB; IHC; ICC; IP. |
| PAN576Hu04 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)多克隆抗體 | WB; IHC; ICC; IP. |
| PAN576Hu01 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)多克隆抗體 | WB; IHC; ICC; IP. |
| LAN576Hu71 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| SEN576Hu | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMN576Hu | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Diabetes Research and Clinical Practice | Serum irisin levels in new-onset type 2 diabetes [PubMed: 23369227] |
| Journal of diabetes and its complications | Lower circulating irisin is associated with type 2 diabetes mellitus [Pubmed: 23619195] |
| Horm Metab Res. | Inconsistency in circulating irisin levels: what is really happening [Pubmed:24459033] |
| Int J Obes (Lond). | Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in mice [Pubmed:25199621] |
| Molecular and Cellular Endocrinology | Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice [Pubmed:25576856] |
| journal of diabetes | Lower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysis [PubMed: 25494632] |
| The Journal of Maternal-Fetal & Neonatal Medicine | Maternal circulating levels of irisin in intrahepatic cholestasis of pregnancy [PubMed: 26689349] |
| Hormone and Metabolic Research | Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis [Pubmed:27300472] |
| Nature Reviews Endocrinology | Physiology and role of irisin in glucose homeostasis. [pubmed:28211512] |
| Journal of Molecular and Cellular Cardiology | Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice [pubmed:27638193] |
| Biochemical and Biophysical Research Communications | Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma [pubmed:28867187] |
| PLoS One | Differential actions of PPAR-α and PPAR-β/δ on beige adipocyte formation: A study in the subcutaneous white adipose tissue of obese male mice [Pubmed:29351550] |
| International Brazilian Journal of?Urology | The Diagnostic Value of FNDC5/Irisin in Renal Cell Cancer. [Pubmed:29522296] |
| Redox Biology | Irisin alleviates liver ischemia-reperfusion injury by inhibiting excessive mitochondrial fission, promoting mitochondrial biogenesis and decreasing oxidative?… [Doi: 10.1016/j.redox.2018.10.019] |
| Antioxidants & redox signaling | Low serum irisin concentration is associated with poor outcomes in patients with acute pancreatitis and irisin administration protects against experimental acute?… [Pubmed: 31250660] |
| Journal of Maternal-Fetal & Neonatal Medicine | Maternal serum, placental, and umbilical venous blood irisin levels in intrahepatic cholestasis of pregnancy [Pubmed: 31590596] |
| Biomed Pharmacother | Identification of irisin as a therapeutic agent that inhibits oxidative stress and fibrosis in a murine model of chronic pancreatitis [Pubmed: 32199226] |
| Irisin Improves Autophagy of Aged Hepatocytes via Increasing Telomerase Activity in Liver Injury [Pubmed: 31976032] | |
| Serum Irisin Predicts Posthepatectomy Complications in Patients with Hepatocellular Carcinoma [Pubmed: 31976024] | |
| DOMESTIC ANIMAL ENDOCRINOLOGY | The myokine Irisin: localization and effects in swine late medium and large antral ovarian follicle [Pubmed: 33120167] |
| Journal of Biomaterials and Tissue Engineering | The Combination of Aerobic and Resistance Exercise Induces Weight Loss via the PGC-1α/Irisin/UCP-1 Pathway [] |
| Evaluation of a recombinant bacillus calmette-guérin vaccine expressing P39-L7/L12 of Brucella melitensis: An immunization strategy against brucellosis in BALB/c … [] | |
| Eur Rev Med Pharmacol Sci | Salivary Irisin: potential inflammatory biomarker in recurrent apthous stomatitis patients [33755963] |
| Metabolites | Pattern of Adiponectin, Osteocalcin, Irisin, FGF-21, and MCP-1 According to the Body Size Phenotype: Could They Be Markers of Metabolic Health in Mexican-Mestizo?… [34822430] |
| Eat Weight Disord | Time-restricted feeding prevents metabolic diseases through the regulation of galanin/GALR1 expression in the hypothalamus of mice [34370270] |
| Ir J Med Sci | Eight-week exercise program improved the quality of life of Alzheimer's patients through functional, cognitive, and biochemical parameters [Pubmed:35604540] |
| Biomed Pharmacother | Irisin attenuates sepsis-induced cardiac dysfunction by attenuating inflammation-induced pyroptosis through a mitochondrial ubiquitin ligase-dependent?… [Pubmed:35653888] |
| Journal of King Saud University - Science | Interaction of nitric oxide synthase and mitochondrial ATP-sensitive potassium channels in protective impacts of combination therapy with irisin?… [] |
留言咨詢
